PLRX today
$0.74-$0.04 (-4.81%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $0.98
Key levels
Resistance$0.88
Resistance$0.84
Latest news & SEC filings
NewsPliant Therapeutics hires Craig Blanchette to lead siRNA research
ProductPliant Therapeutics gets FDA fast track for PLN-101095 with pembrolizumab
All PLRX news →About Pliant Therapeutics
Pliant Therapeutics is a clinical-stage biopharmaceutical company that develops treatments for fibrotic diseases. Its lead product candidate, PLN-101095, is being tested both alone and alongside pembrolizumab for cancer. The company operates in the United States and may pursue approvals in other countries.
Based on the company's 10-K filed Mar 11, 2026.
Nasdaq · Healthcare
PLIANT THERAPEUTICS, INC. (PLRX)
What Is the Price Target for PLRX?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is PLRX a Buy or Sell Right Now?
Thesis
- •Revenue growing -83.7% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PLRX.
Start Free Trial →Is PLRX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B
Fair Value
$6.10
12
Moat Score
NONE
3/9
Piotroski Score
-6.0
Altman Z-Score
What Is Smart Money Doing with PLRX?
Insider Signal
SELLING
0 buys / 4 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PLRX Growth Story
Revenue YoY
-83.7%
3yr Revenue CAGR
N/A%
EPS Growth YoY
29.97%
FCF Growth YoY
19.2%
Revenue Trend
DECLINING
Dark Pool Trades for PLRX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PLRX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:48:40 | $0.75 | 1,500 | $$1K | BUY |
| 19:23:39 | $0.75 | 5,600 | $$4K | BUY |
| 19:23:39 | $0.75 | 5,600 | $$4K | BUY |
| 19:11:48 | $0.75 | 1,700 | $$1K | BUY |
| 19:11:25 | $0.74 | 1,300 | $$968 | SELL |
5 dark pool trades shown · $$12K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for PLIANT THERAPEUTICS, INC. (PLRX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PLRX — frequently asked questions
What is PLRX stock price today?
PLIANT THERAPEUTICS, INC. (PLRX) is at $0.74, down 4.81% (-$0.04) at the Nov 12, 2026 close.
Why is PLRX stock moving today?
Latest PLRX news — Oct 20, 2026: Pliant Therapeutics hires Craig Blanchette to lead siRNA research · Aug 18, 2026: Pliant Therapeutics gets FDA fast track for PLN-101095 with pembrolizumab
What do analysts rate PLRX?
Analyst ratings for PLRX: 0 Buy, 3 Hold, 1 Sell — consensus Hold.
Did PLRX beat earnings?
PLRX last reported on Aug 11, 2026: EPS -$0.36 vs -$0.34 expected — a miss of 5.3%.
Does PLRX pay a dividend?
PLRX does not currently pay a dividend.
How much debt does PLRX have?
PLIANT THERAPEUTICS, INC. reported $0M of debt and $25M of cash (Jun 30, 2026).
What are PLRX support and resistance levels?
Resistance: $0.84, $0.88, $0.98.
What are insiders doing with PLRX?
Insider activity: SELLING, 0 buys and 4 sells in the last 90 days.
What is the latest news on PLRX?
Oct 20, 2026: Pliant Therapeutics hires Craig Blanchette to lead siRNA research · Aug 18, 2026: Pliant Therapeutics gets FDA fast track for PLN-101095 with pembrolizumab